The first poster demonstrates proof-of-concept data that Aqtual's therapy selection test can predict treatment response in patients with RA. The second poster provides an interim analysis from ...
A team led by Mass General Brigham researchers demonstrated that inebilizumab reduced the risk of symptoms by 87% in patients with the rare affliction known as immunoglobulin G4–related disease (IgG4- ...
Researchers have demonstrated that inebilizumab reduced the risk of symptoms by 87 percent in patients with the rare affliction known as immunoglobulin G4-related disease (IgG4-RD).
Current regulatory guidelines requiring fracture outcomes have curtailed innovation in the treatment of this significant disease due to ethical, time and sizing of studies required to evaluate new ...
People with rheumatoid arthritis often develop osteoporosis ... plan to use these results as a starting point to develop new treatment options for patients suffering from these two linked diseases.
Information was obtained from the MEPS from the years 1999 to 2005 for all respondents ages 50 years and older who self-reported as having osteoporosis. In the examination of trends in medication ...